SCIENTURE (SCNX) Drug Added to Formularies at Three U.S. Hospitals

ScienSURE's drug Arbli has been added to the formularies of three leading U.S. pediatric academic medical centers and hospitals. This institutional formulary win is expected to expand Arbli's presence in pediatric care, coinciding with sequentially increasing wholesale orders. Arbli targets the approximately $219 million U.S. Losartan market, which accounts for roughly 72 million prescriptions annually.